Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
A subcutaneous formulation of Takeda Pharmaceutical’s inflammatory bowel disease treatment Entyvio (vedolizumab) achieved the primary endpoint in a global PIII study gauging it as a maintenance therapy for moderately to severely active Crohn’s disease (CD), according to the latest data.…
To read the full story
Related Article
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Entyvio’s SC Form Accepted by US FDA for Review: Takeda
May 13, 2019
- Entyvio SC Form Now under EMA Review: Takeda
April 2, 2019
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda
July 20, 2018
BUSINESS
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Ultomiris, Soliris Bolster Labels for gMG in Japan: Alexion
April 3, 2025
- Shionogi Grants Cefiderocol Rights to Clinigen Unit in Australia/New Zealand
April 3, 2025
- Cheplapharm Completes Tarceva Transfer, Announces Hydrea Acquisition in Japan
April 3, 2025
- Boehringer Will Wait and See Impact of Trump Tariffs, FDA Layoffs: CEO
April 3, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…